Wasdell opens doors at EU headquarters

By Melissa Fassbender

- Last updated on GMT

(Image: Wasdell Group)
(Image: Wasdell Group)

Related tags Wasdell Brexit Manufacturing

The company initiates operations at its new EU headquarters in Dundalk, Ireland after receiving its manufacturing and importation authorization license from the HPRA.

Wasdell Group in December 2017​ announced the investment of €30m ($33.64) to build the new EU headquarters, and work began on the facility in September 2018​.

A successful Health Products Regulatory Authority (HPRA) inspection was conducted in late 2018 at the location, enabling Wasdell to perform QP batch certification and release of pharmaceutical products into Europe, as part of its Brexit preparations.

The 90,000 square foot facility, located in the new IDA Technology and Science Park, features 11 production suites and temperature controlled high-bay warehouses.

According to the company, the facility boosts its capacity in clinical and commercial packaging, distribution and logistics, as well as qualified persons (QP) services.

Vincent Dunne, CEO said: “We are seeing growing demand for our services, especially from companies that wish to outsource their entire product lifecycle from clinical services and EU launch to manufacturing, packaging and distribution. The new facility strengthens our offering, allowing us to further support our customers.”

“With over 75% of our turnover as export business, our new facility will serve our large client base in Europe and better support our growing US customer portfolio as they look to outsource their European supply chain operations from clinical projects to routine supply,”​ he added.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more